回复：瑞可利司他并非高度选择性的组蛋白去乙酰化酶6抑制剂。 - Suppr

Suppr

超能文献

Reply to: Ricolinostat is not a highly selective HDAC6 inhibitor.

作者信息

Silva Jose, Yu Jiyang, Kalinsky Kevin

机构信息

Department of Pathology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA.

Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.

出版信息

Nat Cancer. 2023 Jun;4(6):809-811. doi: 10.1038/s43018-023-00583-2. Epub 2023 Jun 15.

DOI:10.1038/s43018-023-00583-2

PMID:37322366

Abstract

摘要

相似文献

Reply to: Ricolinostat is not a highly selective HDAC6 inhibitor.回复：瑞可利司他并非高度选择性的组蛋白去乙酰化酶6抑制剂。

Nat Cancer. 2023 Jun;4(6):809-811. doi: 10.1038/s43018-023-00583-2. Epub 2023 Jun 15.

Ricolinostat is not a highly selective HDAC6 inhibitor.瑞可利司他不是一种高度选择性的组蛋白去乙酰化酶6（HDAC6）抑制剂。

Nat Cancer. 2023 Jun;4(6):807-808. doi: 10.1038/s43018-023-00582-3. Epub 2023 Jun 15.

Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.瑞克林司他（ACY-1215）诱导的聚集物形成抑制加速了卡非佐米诱导的多发性骨髓瘤细胞死亡。

Br J Haematol. 2015 May;169(3):423-34. doi: 10.1111/bjh.13315. Epub 2015 Feb 23.

In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells.HDAC6抑制剂ricolinostat（ACY1215）与不可逆蛋白酶体抑制剂卡非佐米在非霍奇金淋巴瘤细胞中的体外和体内相互作用

Mol Cancer Ther. 2014 Dec;13(12):2886-97. doi: 10.1158/1535-7163.MCT-14-0220. Epub 2014 Sep 19.

Human ATP-binding cassette transporters ABCB1 and ABCG2 confer resistance to histone deacetylase 6 inhibitor ricolinostat (ACY-1215) in cancer cell lines.人类 ATP 结合盒转运蛋白 ABCB1 和 ABCG2 使癌细胞系对组蛋白去乙酰化酶 6 抑制剂 ricolinostat（ACY-1215）产生耐药性。

Biochem Pharmacol. 2018 Sep;155:316-325. doi: 10.1016/j.bcp.2018.07.018. Epub 2018 Jul 17.

Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.HDAC6 激活 MET 信号为弥漫性大 B 细胞淋巴瘤的新型 ricolinostat 和克唑替尼联合治疗策略提供了依据。

J Pathol. 2018 Oct;246(2):141-153. doi: 10.1002/path.5108. Epub 2018 Aug 20.

ACY 1215, a histone deacetylase 6 inhibitor, inhibits cancer cell growth in melanoma.ACY-1215，一种组蛋白去乙酰化酶 6 抑制剂，可抑制黑色素瘤中的癌细胞生长。

J Biol Regul Homeost Agents. 2018 Jul-Aug;32(4):851-858.

Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma.利洛司他联合硼替佐米和地塞米松治疗复发/难治性多发性骨髓瘤：首个选择性组蛋白去乙酰化酶 6 抑制剂

Clin Cancer Res. 2017 Jul 1;23(13):3307-3315. doi: 10.1158/1078-0432.CCR-16-2526. Epub 2017 Jan 4.

Ricolinostat (ACY-1215) inhibits VEGF expression via PI3K/AKT pathway and promotes apoptosis in osteoarthritic osteoblasts.瑞利昔单抗（ACY-1215）通过 PI3K/AKT 通路抑制 VEGF 表达并促进骨关节炎成骨细胞凋亡。

Biomed Pharmacother. 2019 Oct;118:109357. doi: 10.1016/j.biopha.2019.109357. Epub 2019 Aug 21.

Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.里西利司他联合来那度胺和地塞米松治疗复发/难治性多发性骨髓瘤的多中心 1b 期试验。

Lancet Oncol. 2016 Nov;17(11):1569-1578. doi: 10.1016/S1470-2045(16)30375-8. Epub 2016 Sep 17.

引用本文的文献

Phase separation rewires chromatin in breast cancer.相分离重塑乳腺癌中的染色质。

Nat Cancer. 2024 Nov;5(11):1602-1604. doi: 10.1038/s43018-024-00843-9.

本文引用的文献

Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer.基于网络的 HDAC6 活性评估可预测乳腺癌患者对 HDAC6 抑制剂 ricolinostat 的临床前和临床反应。

Nat Cancer. 2023 Feb;4(2):257-275. doi: 10.1038/s43018-022-00489-5. Epub 2022 Dec 30.

Targeting the MYC interaction network in B-cell lymphoma via histone deacetylase 6 inhibition.通过组蛋白去乙酰化酶 6 抑制靶向 B 细胞淋巴瘤中的 MYC 相互作用网络。

Oncogene. 2022 Sep;41(40):4560-4572. doi: 10.1038/s41388-022-02450-3. Epub 2022 Sep 6.

Target deconvolution of HDAC pharmacopoeia reveals MBLAC2 as common off-target.靶向去卷积 HDAC 药理学揭示 MBLAC2 为常见的脱靶。

Nat Chem Biol. 2022 Aug;18(8):812-820. doi: 10.1038/s41589-022-01015-5. Epub 2022 Apr 28.

An HDAC6 inhibitor reverses chemotherapy-induced mechanical hypersensitivity via an IL-10 and macrophage dependent pathway.一种组蛋白去乙酰化酶 6 抑制剂通过白细胞介素 10 和巨噬细胞依赖途径逆转化疗引起的机械性超敏反应。

Brain Behav Immun. 2022 Feb;100:287-296. doi: 10.1016/j.bbi.2021.12.005. Epub 2021 Dec 13.

First-in-Class Selective HDAC6 Inhibitor (ACY-1215) Has a Highly Favorable Safety Profile in Patients with Relapsed and Refractory Lymphoma.首类选择性组蛋白去乙酰化酶 6 抑制剂（ACY-1215）在复发/难治性淋巴瘤患者中具有良好的安全性。

Oncologist. 2021 Mar;26(3):184-e366. doi: 10.1002/onco.13673. Epub 2021 Feb 9.

Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer.HDAC6抑制剂瑞可林司他与紫杉醇联合用于复发性卵巢癌、输卵管癌或原发性腹膜癌的简化Ib期研究结果。

Gynecol Oncol Rep. 2019 Aug 10;29:118-122. doi: 10.1016/j.gore.2019.07.010. eCollection 2019 Aug.

Selective pharmacological inhibitors of HDAC6 reveal biochemical activity but functional tolerance in cancer models.选择性组蛋白去乙酰化酶 6 抑制剂在癌症模型中揭示了生化活性但存在功能耐受。

Int J Cancer. 2019 Aug 1;145(3):735-747. doi: 10.1002/ijc.32169. Epub 2019 Feb 20.

HDAC6 differentially regulates autophagy in stem-like versus differentiated cancer cells.HDAC6 差异化调控干性肿瘤细胞与分化肿瘤细胞中的自噬。

Autophagy. 2019 Apr;15(4):686-706. doi: 10.1080/15548627.2018.1548547. Epub 2018 Dec 4.

Clin Cancer Res. 2017 Jul 1;23(13):3307-3315. doi: 10.1158/1078-0432.CCR-16-2526. Epub 2017 Jan 4.

Down-regulation of deacetylase HDAC6 inhibits the melanoma cell line A375.S2 growth through ROS-dependent mitochondrial pathway.去乙酰化酶HDAC6的下调通过活性氧依赖性线粒体途径抑制黑色素瘤细胞系A375.S2的生长。

PLoS One. 2015 Mar 16;10(3):e0121247. doi: 10.1371/journal.pone.0121247. eCollection 2015.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验